CPT-31 is under clinical development by Navigen and currently in Phase I for Human Immunodeficiency Virus (HIV) Infections (AIDS). According to GlobalData, Phase I drugs for Human Immunodeficiency Virus (HIV) Infections (AIDS) have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CPT-31’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CPT-31 overview

CPT-31 (CPT31-LA) is under development for the treatment of HIV infections. It is a synthetic, non-degradable trimeric D-peptide that binds to highly conserved HIV gp41 pocket and potently blocks HIV entry. It is a long-acting depot formulation. This drug candidate is developed based on D-peptide Discovery Platform. It is administered through subcutaneous route.

Navigen overview

Navigen is a drug development company which develops novel peptide medicines. The company’s pipeline products include D-Peptides and ARF6 inhibitors. It offers D-peptides development programs. Navigen’s ARF6 inhibitors is used to treat disease such as uveal melanoma, acute lung injury, malignant sarcoma, acute respiratory distress syndrome, multi-drug resistant gram negative bacterial pneumonia, and diabetic retinopathy. The company conducts ongoing programs to address human immunodeficiency virus (HIV), respiratory syncytial virus (RSV) and other diseases. Navigen is headquartered in Salt Lake City, Utah, the US.

For a complete picture of CPT-31’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.